PsiOxus, the gene therapy for cancer company, today announced that it has started a clinical trial with NG-641, a four transgene tumor-microenvironment modifying cancer gene therapy. This is the first… read more →
March 13, 2019 – OXFORD, UK – PsiOxus Therapeutics Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started dosing NG-350A, an antibody based cancer gene… read more →
PsiOxus Therapeutics Ltd. (PsiOxus) and the Parker Institute for Cancer Immunotherapy (Parker Institute) announce a research project to investigate the use of PsiOxus’ virus-based gene therapy for treating solid tumors… read more →
December 12, 2017 –OXFORD, UK – PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has… read more →
Treating solid tumors through the systemic delivery of oncolytic viruses. PsiOxus is very proud to also announce that we have been recognised by Fierce Biotech in this year’s Fierce 15.… read more →
The Sunday Times Hiscox Tech Track 100 league table ranks Britain’s 100 private tech (TMT) companies with the fastest-growing sales over their latest three years. It is compiled by Fast Track… read more →
(OXFORD, United Kingdom and PHILADELPHIA, United States. 16th August 2017) PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as… read more →
June 13th, 2017 – OXFORD, UK – PsiOxus Therapeutics, Ltd. (PsiOxus), the cancer therapeutics company, today announced expansion of operations into a 21,000 sq ft state-of-the-art facility on the Abingdon… read more →
DECEMBER 20th, 2016 – NEW YORK and OXFORD, UK – Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights… read more →
OXFORD, UK and BALTIMORE, MD, USA Avidea Technologies Inc. (“Avidea”), a biotechnology company, and PsiOxus Therapeutics Ltd. (“PsiOxus”), the immuno-oncology company, today announced an agreement licensing PsiOxus’ PolyMAP multivalent adjuvant… read more →
